GlassScriptPhysician profile
Kareen Champagne
NPI 1255828372
$488.02
in general payments reported to CMS, 2019-2025
11 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $62.63 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $96.63 | 2025 | |
| Amgen INC. | $95.27 | 2024-2025 | Evenity, Prolia, Tepezza |
| Cequr Corporation | $57.44 | 2025 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $51.33 | 2025 | Gvoke Hypopen, Recorlev |
| Recordati_rare_diseases_inc. | $33.62 | 2025 | Isturisa |
| Novo Nordisk INC | $32.41 | 2024-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $28.71 | 2025 | Mounjaro, Zepbound |
| Ascendis Pharma Endocrinology INC | $25.48 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $24.33 | 2025 | Unithroid |
| Sequel Med Tech, LLC | $22.79 | 2025 | Twiist |
| Insulet Corporation | $20.01 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kareen Champagne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.